Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modified-release tacrolimus.

Marie A Chisholm1, Matthew D Middleton

  • 1College of Pharmacy, University of Georgia, Augusta, GA 30912-2450, USA. Mchishol@mail.mcg.edu

The Annals of Pharmacotherapy
|February 2, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of characteristics of renal transplant recipients with clinicians' perceptions of adherence to immunosuppressant therapy.

Transplantation·2007
Same author

Effects of a medication assistance program with medication therapy management on the health of renal transplant recipients.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2007
Same author

Predicting adherence to immunosuppressant therapy: a prospective analysis of the theory of planned behaviour.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2007
Same author

Influence of economic and demographic factors on quality of life in renal transplant recipients.

Clinical transplantation·2007
Same author

Is age associated with the number or types of medications prescribed to renal transplant recipients?

Journal of the American Geriatrics Society·2007
Same author

A renal transplantation advanced pharmacy practice experience.

American journal of pharmaceutical education·2006
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

Modified-release tacrolimus (MR-4) demonstrates pharmacokinetic, efficacy, and safety profiles comparable to standard tacrolimus. Once-daily MR-4 offers an advantage in preventing graft rejection, though further adherence studies are needed.

Area of Science:

  • Pharmacology and Transplantation Medicine
  • Immunosuppressive Therapy Research
  • Drug Formulation and Delivery Systems

Background:

  • Tacrolimus is a vital calcineurin inhibitor for preventing solid-organ graft rejection.
  • Current tacrolimus formulations require twice-daily dosing, potentially impacting patient adherence.
  • Modified-release formulations aim to improve dosing convenience and therapeutic outcomes.

Purpose of the Study:

  • To review and compare the pharmacokinetics, efficacy, and safety of modified-release tacrolimus (MR-4) against non-modified-release tacrolimus.
  • To assess the equivalence of MR-4 to standard tacrolimus in clinical trials.
  • To evaluate the potential benefits of MR-4's once-daily dosing regimen.

Main Methods:

  • Comprehensive literature search of PubMed/MEDLINE (1966-July 2005) using keywords: MR-4, tacrolimus, FK506, Prograf, transplantation, calcineurin inhibitors, immunosuppression.

Related Experiment Videos

  • Inclusion of English-language, published randomized clinical trials evaluating MR-4 and tacrolimus for graft rejection prevention.
  • Data extraction from identified publications, meeting abstracts, and manufacturer information.

    • Main Results:

    • MR-4 exhibits similar pharmacokinetic profiles to standard tacrolimus in healthy volunteers and transplant recipients (renal, liver).
    • Comparable efficacy and safety profiles were observed between MR-4 and standard tacrolimus.
    • A 1:1 conversion from twice-daily tacrolimus to once-daily MR-4 is considered safe, with similar target whole blood trough concentrations.

    Conclusions:

    • Short-term clinical trials suggest MR-4 possesses similar efficacy and safety to tacrolimus.
    • The once-daily administration of MR-4 presents a dosing advantage for preventing graft rejection compared to existing calcineurin inhibitors.
    • Further adherence studies are required to evaluate the clinical and economic outcomes associated with MR-4.